Profusa, Inc. (PFSA)

Profusa, Inc. is a digital health company developing tissue-integrated biosensors intended to provide continuous, long-term monitoring of body chemistry. Its technology is based on small, flexible hydrogel sensors placed just under the skin that integrate with surrounding tissue and are designed to avoid the foreign-body response that limits many implanted devices.

The sensors are read optically by a reader worn on the skin, allowing data such as tissue oxygen and other biomarkers to be transmitted to a smartphone or clinical system. Profusa has pursued applications in peripheral artery disease and wound care, and has explored uses in metabolic monitoring and other chronic conditions. Its Lumee oxygen platform is among its best-known products.

Profusa is based in California and became a publicly traded company in 2025 through a business combination with NorthView Acquisition Corp., a special purpose acquisition company. Its common stock trades on Nasdaq.